The initiatives are being funded with C$24 million over two years and will focus on acute leukemia, immuno-oncology, and brain, ovarian, and pancreatic cancer.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
Canada's Hospital for Sick Children and the University Health Network's Princess Margaret Cancer Centre are piloting a new IT infrastructure for analyzing genetic and other kinds of biomedical data.
This story has been updated to include additional information from a US survey on people's attitudes about cost of genetic testing. Originally published June 4.
A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.
